Giuseppe Viscardi

2.9k total citations
46 papers, 871 citations indexed

About

Giuseppe Viscardi is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Immunology. According to data from OpenAlex, Giuseppe Viscardi has authored 46 papers receiving a total of 871 indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Oncology, 26 papers in Pulmonary and Respiratory Medicine and 7 papers in Immunology. Recurrent topics in Giuseppe Viscardi's work include Cancer Immunotherapy and Biomarkers (15 papers), Lung Cancer Treatments and Mutations (14 papers) and Lung Cancer Diagnosis and Treatment (10 papers). Giuseppe Viscardi is often cited by papers focused on Cancer Immunotherapy and Biomarkers (15 papers), Lung Cancer Treatments and Mutations (14 papers) and Lung Cancer Diagnosis and Treatment (10 papers). Giuseppe Viscardi collaborates with scholars based in Italy, United States and France. Giuseppe Viscardi's co-authors include Floriana Morgillo, Fortunato Ciardiello, Raimondo Di Liello, Carminia M. Della Corte, Morena Fasano, Carminia Maria Della Corte, Francesca Sparano, Giovanna Esposito, Federica Papaccio and Filomena Velleca and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and JNCI Journal of the National Cancer Institute.

In The Last Decade

Giuseppe Viscardi

42 papers receiving 855 citations

Peers

Countries citing papers authored by Giuseppe Viscardi

Since Specialization

Citations

This map shows the geographic impact of Giuseppe Viscardi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Giuseppe Viscardi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Giuseppe Viscardi more than expected).

Fields of papers citing papers by Giuseppe Viscardi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Giuseppe Viscardi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Giuseppe Viscardi. The network helps show where Giuseppe Viscardi may publish in the future.

Co-authorship network of co-authors of Giuseppe Viscardi

This figure shows the co-authorship network connecting the top 25 collaborators of Giuseppe Viscardi. A scholar is included among the top collaborators of Giuseppe Viscardi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Giuseppe Viscardi. Giuseppe Viscardi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Unraveling Resistance in Lung Cancer Immunotherapy: Clinical Milestones, Mechanistic Insights, and Future Strategies 2025 ·International Journal of Molecular Sciences ·(unknown), (unknown), Giuseppe Viscardi, Lucio Pastore, Giuseppe Castaldo, Fabio Perrotta, (unknown), Andrea Bianco, Filippo Scialò	0
2	Neoadjuvant vs perioperative chemo-immunotherapy according to pathological response in resectable non-small cell lung cancer: a reconstructed individual patient data meta-analysis 2025 ·JNCI Journal of the National Cancer Institute ·(unknown), (unknown), Alberto Servetto, Biagio Ricciuti, Daniele Marinelli, Alessandra Bulotta, Giulia Veronesi, Marina Chiara Garassino, Valter Torri, Benjamin Besse, Giuseppe Viscardi, Roberto Ferrara	1
3	Attrition with adjuvant, neoadjuvant, and perioperative immunotherapy-based treatment protocols in patients with resectable non-small-cell lung cancer. A meta-analysis of prospective trials 2025 ·Lung Cancer ·Francesco Guerrera, Filippo Tommaso Gallina, Eleonora Balzani, Francesca Ambrosi, Alessandro Di Federico, Eleonora Faccioli, (unknown), Roberto Ferrara, Alessandra Ferro, (unknown), Raffaele Giusti, Carlo Greco, (unknown), Daniele Marinelli, (unknown), Alessandra Pittaro, Matteo Sepulcri, Giuseppe Viscardi, Pietro Bertoglio	1
4	Current diagnostic and therapeutical approaches to bone metastases in patients with non-small cell lung cancer: A cross-sectional study 2025 ·Lung Cancer ·Alice Avancini, Niccolò Giaj‐Levra, Gabriele Minuti, (unknown), Francesca Colonese, Alessandro Di Federico, Alessandra Fozza, (unknown), Emanuela Olmetto, (unknown), Maria Lucia Reale, (unknown), Elisa Roca, Claudio Sini, Giuseppe Viscardi, Francesco Passiglia, Sara Pilotto	0
5	Unleashing precision: A review of targeted approaches in pleural mesothelioma 2024 ·Critical Reviews in Oncology/Hematology ·Mario Occhipinti, Marta Brambilla, Raimondo Di Liello, (unknown), (unknown), Rita Leporati, (unknown), Fabiana Vitiello, (unknown), Sara Manglaviti, (unknown), Laura Mazzeo, Claudia Proto, Arsela Prelaj, Roberto Ferrara, Carminia M. Della Corte, Giuseppe Lo Russo, Filippo de Braud, Monica Ganzinelli, Giuseppe Viscardi	6
6	Evaluation of Major Pathologic Response and Pathologic Complete Response as Surrogate End Points for Survival in Randomized Controlled Trials of Neoadjuvant Immune Checkpoint Blockade in Resectable in NSCLC 2024 ·Journal of Thoracic Oncology ·(unknown), Robert B. Cameron, A. Esposito, (unknown), Luca Porcu, (unknown), Giuseppe Viscardi, Roberto Ferrara, Giulia Veronesi, Patrick M. Forde, Janis M. Taube, Everett E. Vokes, Christine M. Bestvina, James M. Dolezal, Matteo Antonio Sacco, Marta Monteforte, Tina Cascone, Marina Chiara Garassino, Valter Torri	23
7	Analysis of phase III clinical trials in metastatic NSCLC to assess the correlation between QoL results and survival outcomes 2023 ·BMC Medicine ·Alberto Servetto, Massimo Di Maïo, (unknown), Fabiana Napolitano, (unknown), (unknown), Giuseppe Viscardi, Antonio Santaniello, Luigi Formisano, Roberto Bianco	3
8	Moving Immune Checkpoint Inhibitors to Early Non-Small Cell Lung Cancer: A Narrative Review 2022 ·Cancers ·Giuseppe Viscardi, Fabiana Vitiello, Alberto Servetto, Valerio Gristina, Elio Gregory Pizzutilo, (unknown), (unknown), (unknown), (unknown), (unknown), Luigi Aronne, (unknown), Filomena Napolitano, (unknown), Francesca Caputo, (unknown), (unknown), (unknown), Danilo Rocco, Vincenzo Montesarchio	4
9	Health-related quality of life is underestimated and underreported in phase III clinical trials in NSCLC 2022 ·Lung Cancer ·(unknown), (unknown), (unknown), Giuseppe Viscardi, (unknown), Fabiana Napolitano, Antonio Santaniello, Luigi Formisano, Roberto Bianco, Alberto Servetto	6
10	A Trimodality, Four-Step Treatment including Chemotherapy, Pleurectomy/Decortication and Radiotherapy in Early-Stage Malignant Pleural Mesothelioma: A Single-Institution Retrospective Case Series Study 2021 ·Cancers ·Giovanni Vicidomini, Carminia Maria Della Corte, (unknown), Raimondo Di Liello, Salvatore Cappabianca, Alfonso Fiorelli, Valerio Nardone, Gaetana Messina, Giuseppe Viscardi, Angelo Sangiovanni, Riccardo Monti, Marina Accardo, Floriana Morgillo, Fortunato Ciardiello, Renato Franco, Mario Santini	3
11	Chemotherapy-induced bowel ischemia: diagnostic imaging overview 2021 ·Abdominal Radiology ·Alfonso Reginelli, Angelo Sangiovanni, Giovanna Vacca, Maria Paola Belfiore, (unknown), Giuseppe Viscardi, Alfredo Clemente, Fabrizio Urraro, Salvatore Cappabianca	5
12	Induction of natural killer antibody-dependent cell cytotoxicity and of clinical activity of cetuximab plus avelumab in non-small cell lung cancer 2020 ·ESMO Open ·Morena Fasano, Carminia Maria Della Corte, Raimondo Di Liello, Giusi Barra, Francesca Sparano, Giuseppe Viscardi, Maria Lucia Iacovino, (unknown), Vincenzo Famiglietti, Vincenza Ciaramella, Flora Cimmino, Mario Capasso, Achille Iolascon, Vincenzo Sforza, Alessandro Morabito, Evaristo Maiello, Fortunato Ciardiello, Floriana Morgillo	30
13	1278P Hyperprogressive disease (HPD) upon first-line PD-1/PD-L1 inhibitors (ICI) as single agent or in combination with platinum-based chemotherapy in non-small cell lung cancer (NSCLC) patients (pts) 2020 ·Annals of Oncology ·Roberto Ferrara, Francesco Facchinetti, Giuseppina Calareso, (unknown), Diego Signorelli, Claudia Proto, Arsela Prelaj, Charles Naltet, Pernelle Lavaud, (unknown), Giuseppe Viscardi, Giulia Galli, Alessandro De Toma, Antonia Martinetti, Fabrice Barlési, David Planchard, J.C. Soria, Marina Chiara Garassino, Benjamin Besse, Giuseppe Lo Russo	7
14	1388P Poziotinib in advanced NSCLC with EGFR or HER2 exon 20 insertion mutation: Initial results from a single site expanded access program 2020 ·Annals of Oncology ·Arsela Prelaj, (unknown), Claudia Proto, Giuseppe Lo Russo, Diego Signorelli, Roberto Ferrara, Giulia Galli, Alessandro De Toma, Giuseppe Viscardi, Marta Brambilla, Riccardo Lobefaro, Sara Manglaviti, Mario Occhipinti, (unknown), Rosaria Gallucci, (unknown), Nicoletta Zilembo, Francesca Gabriella Greco, Valter Torri, Marina Chiara Garassino	5
15	1329P Immune checkpoint inhibitors in advanced NSCLC patients with poor performance status: The role of clinical-pathological variables and inflammatory biomarkers in a real world experience 2020 ·Annals of Oncology ·Riccardo Lobefaro, Giuseppe Viscardi, Raimondo Di Liello, (unknown), Maria Lucia Iacovino, Francesca Sparano, Carminia Maria Della Corte, Roberto Ferrara, Diego Signorelli, Claudia Proto, Arsela Prelaj, Giulia Galli, Alessandro De Toma, Marta Brambilla, Monica Ganzinelli, (unknown), Filippo de Braud, Floriana Morgillo, Marina Chiara Garassino, Giuseppe Lo Russo	1
16	Integrating clinical and biological prognostic biomarkers in patients with advanced NSCLC treated with immunotherapy: the DEMo score system 2020 ·Translational Lung Cancer Research ·Arsela Prelaj, Claudia Proto, Giuseppe Lo Russo, Diego Signorelli, Roberto Ferrara, Mavis Mensah, Giulia Galli, Alessandro De Toma, Giuseppe Viscardi, Marta Brambilla, Riccardo Lobefaro, (unknown), Francesco Trovò, Valter Torri, Gabriella Sozzi, Marina Chiara Garassino, Mattia Boeri	6
17	Activity and molecular targets of pioglitazone via blockade of proliferation, invasiveness and bioenergetics in human NSCLC 2019 ·Journal of Experimental & Clinical Cancer Research ·Vincenza Ciaramella, Ferdinando Carlo Sasso, Raimondo Di Liello, Carminia Maria Della Corte, Giusi Barra, Giuseppe Viscardi, Giovanna Esposito, Francesca Sparano, Teresa Troiani, Erika Martinelli, Michele Orditura, Ferdinando De Vita, Fortunato Ciardiello, Floriana Morgillo	41
18	Atypical haemolytic-uraemic syndrome in patient with metastatic colorectal cancer treated with fluorouracil and oxaliplatin: a case report and a review of literature 2019 ·ESMO Open ·Giuseppe Viscardi, N. Zanaletti, (unknown), Antonello Sica, (unknown), Salvatore Guastafierro, Umberto Bracale, Dario Ribero, Morena Fasano, Stefania Napolitano, Pasquale Vitale, Vincenzo De Falco, Emilio Francesco Giunta, Erika Martinelli, Davide Ciardiello, Fortunato Ciardiello, Teresa Troiani	14
19	Carcinogenesis as a Result of Multiple Inflammatory and Oxidative Hits: a Comprehensive Review from Tumor Microenvironment to Gut Microbiota 2018 ·Neoplasia ·Floriana Morgillo, Marcello Dallio, Carminia M. Della Corte, Antonietta Gerarda Gravina, Giuseppe Viscardi, C. Loguercio, Fortunato Ciardiello, Alessandro Federico	66
20	Acquired resistance mechanism of osimertinib targeting EGFR in human lung cancer 2018 ·Annals of Oncology ·Vincenza Ciaramella, Carminia Maria Della Corte, Giusi Barra, Raimondo Di Liello, Giuseppe Viscardi, Michele Orditura, (unknown), Fortunato Ciardiello, Floriana Morgillo	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact